The chief executive of a Canadian drugmaker is suing a noted short seller for libel after the investor criticized the CEO’s tenure at another drug company, which earlier settled charges of accounting fraud.
WSJ.com: Law, Wall Street Journal: Business: Law
Fri, 07/29/2016 - 4:21pm
The chief executive of a Canadian drugmaker is suing a noted short seller for libel after the investor criticized the CEO’s tenure at another drug company, which earlier settled charges of accounting fraud.